Lexaria Bioscience Corp.

Recent News

Altria Group Invests Up to $12M in Lexaria Bioscience's DehydraTECH(TM) Technology
Kelowna, British Columbia--(Newsfile Corp. - January 17, 2019) - Lexaria Nicotine LLC, (OTCQX: LXRP) (CSE: LXX) a wholly owned subsidiary of Lexaria Bioscience Corp. has entered into a definitive agreement with Altria Group Inc. (NYSE: MO) to fund the research & development of Lexaria's patented DehydraTECH™ technology. Lexaria's DehydraTECH™ enhances the performance of beneficial compounds in ingestible products across four categories: taste & smell, speed of action, bio-absorption and bioavailability. The partnership will explore innovation in oral, reduced-risk nicotine...
2019-01-17 8:30 AM EST
Lexaria Announces Definitive Agreement
Kelowna, British Columbia--(Newsfile Corp. - June 26, 2015) - Lexaria, Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company”) announces it has signed the Definitive Agreement on the sale of its 49% interest in the Burlington MMPR application along with its joint venture partner Enertopia Corp.The Burlington MMPR license application will continue with the process under new ownership and Lexaria could potentially receive approximately 50% of $1,500,000 in milestone payments upon the Burlington facility becoming licensed and operational under the MMPR program....
2015-06-26 9:00 AM EDT
Lexaria Corp. Reports Supreme Court of Canada Rules in Favour of Cannabis Edibles
Kelowna, British Columbia--(Newsfile Corp. - June 23, 2015) - Lexaria, Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company") provides the following information related to the Supreme Court of Canada ruling in the Owen Smith case. This case was related to the use of oils, edibles and forms of cannabis for medical use other than the smoking of dried plant material.On Thursday June 11, The Supreme court of Canada ruled unanimously that the current law governing medical cannabis use in Canada is...
2015-06-23 8:30 AM EDT
Lexaria Focuses on Technology; Sells Burlington MMPR License Application
Kelowna, British Columbia--(Newsfile Corp. - June 12, 2015) - Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the "Company") provides the following update related to the Burlington MMPR license application.Lexaria has made significant gains in developing and implementing certain technologies related to the patent pending methods designed to improve bioavailability of certain molecules, including CBD and THC. As recently reported, Lexaria has now included in its patent pendings, applications for lipophilic delivery of Nicotine, NSAIDs, and certain vitamins. The prospective markets for bioavailable edible...
2015-06-12 9:12 AM EDT
Lexaria Files U.S. Utility and International Patent Applications Encompassing Expanded Uses for Its Core Technology
Kelowna, British Columbia--(Newsfile Corp. - June 11, 2015) - Lexaria, Corp. (OTCQB: LXRP) (CSE: LXX) ("Lexaria" or the "Company") provides the following information regarding existing and new patents pending. Lexaria has initiated the simultaneous filing of a U.S. utility patent application and an International patent application under the Patent Cooperation Treaty (PCT) procedure, both at the U.S. Patent and Trademark Office. These applications follow the Company's 2014 and 2015 family of provisional patent application filings in the U.S. and serve two...
2015-06-11 7:15 AM EDT
Lexaria Enters Services Contract with TDM Financial
Kelowna, British Columbia--(Newsfile Corp. - June 8, 2015) - Lexaria Corp. (OTCQB: LXRP) (CNSX: LXX) (the "Company" or "Lexaria") has signed an IR/PR services agreement with TDM Financial valid for the next 60 days.Lexaria expects to receive marketing expertise, video production services, public relations services, and news distribution to over 700,000 TDM Financial subscribers. Lexaria is paying $18,000 for the services and no shares or share purchase options are being awarded. Services are to begin immediately.Separately, Lexaria has entered a...
2015-06-08 8:09 AM EDT
Lexaria Updates Sales Channels Efforts
Kelowna, British Columbia--(Newsfile Corp. - June 5, 2015) - Lexaria, Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company") provides the following information regarding sales channels that the Company is developing.Lexaria has to date sold small but increasing amounts of ViPovaTM Tea through the ViPova website. The Company has certain marketing strategies under development that could result in meaningful increased awareness and product sales prior to the end of the Company's fiscal year (August 31).To facilitate our sales, Lexaria has signed an...
2015-06-05 8:02 AM EDT
Bioavailability Testing to Commence on Lexaria's Patent-Pending Technology
Kelowna, British Columbia--(Newsfile Corp. - May 20, 2015) - Lexaria, Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company") is pleased to announce it has engaged Absorption Systems LP in the USA, to begin third party in vitro tests using a human intestinal tissue model to evaluate the cannabidiol (CBD) permeability of its patent-pending technology that infuses cannabinoid compounds within lipids.The study will assess CBD permeability achieved with our proprietary ViPova™ tea formulation at multiple sampling time points compared to positive and...
2015-05-20 8:15 AM EDT
Lexaria Closes Financing and Announces Conference Participation
Kelowna, British Columbia--(Newsfile Corp. - May 15, 2015) - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces it has closed the Private Placement financing announced on April 17 for gross proceeds of US$500,000. Lexaria will issue 5,000,000 common shares at US$0.10 and 5,000,000 full warrants that expire on May 15, 2017 with an exercise price of US$0.25. Cash finders' fees of US$32,900 and 329,000 broker's warrants were issued and paid. The broker warrants have an exercise price...
2015-05-15 9:01 AM EDT
Lexaria Intellectual Property Update
Kelowna, British Columbia--(Newsfile Corp. - May 15, 2015) - Lexaria, Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company") provides the following update and information regarding its patent-pending technology; how it relates to the delivery of certain active ingredients such as CBD and THC, and how it relates also to market demand.Lexaria has caused to be filed on April 28, 2015 and May 14, 2015, the latest in a line of provisional patent applications with the United States Patent and Trademark Office...
2015-05-15 8:01 AM EDT

Lexaria Bioscience Corp.

Recent News

Get News by Email

Stock Quote

RSS Feeds

Regulatory Filings

Tell Us Your Story

Cookie Settings

Get News by Email

Stock Quote

RSS Feeds

Regulatory Filings

Tell Us Your Story